Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials.

IF 8.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Diabetologia Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI:10.1007/s00125-024-06225-1
Joseph Mellor, Dmitry Kuznetsov, Simon Heller, Mari-Anne Gall, Myriam Rosilio, Stephanie A Amiel, Mark Ibberson, Stuart McGurnaghan, Luke Blackbourn, William Berthon, Adel Salem, Yongming Qu, Rory J McCrimmon, Bastiaan E de Galan, Ulrik Pedersen-Bjergaard, Joanna Leaviss, Paul M McKeigue, Helen M Colhoun
{"title":"Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials.","authors":"Joseph Mellor, Dmitry Kuznetsov, Simon Heller, Mari-Anne Gall, Myriam Rosilio, Stephanie A Amiel, Mark Ibberson, Stuart McGurnaghan, Luke Blackbourn, William Berthon, Adel Salem, Yongming Qu, Rory J McCrimmon, Bastiaan E de Galan, Ulrik Pedersen-Bjergaard, Joanna Leaviss, Paul M McKeigue, Helen M Colhoun","doi":"10.1007/s00125-024-06225-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims/hypothesis: </strong>Whether hypoglycaemia increases the risk of other adverse outcomes in diabetes remains controversial, especially for hypoglycaemia episodes not requiring assistance from another person. An objective of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo-RESOLVE) project was to create and use a dataset of pooled clinical trials in people with type 1 or type 2 diabetes to examine the association of exposure to all hypoglycaemia episodes across the range of severity with incident event outcomes: death, CVD, neuropathy, kidney disease, retinal disorders and depression. We also examined the change in continuous outcomes that occurred following a hypoglycaemia episode: change in eGFR, HbA<sub>1c</sub>, blood glucose, blood glucose variability and weight.</p><p><strong>Methods: </strong>Data from 84 trials with 39,373 participants were pooled. For event outcomes, time-updated Cox regression models adjusted for age, sex, diabetes duration and HbA<sub>1c</sub> were fitted to assess association between: (1) outcome and cumulative exposure to hypoglycaemia episodes; and (2) outcomes where an acute effect might be expected (i.e. death, acute CVD, retinal disorders) and any hypoglycaemia exposure within the last 10 days. Exposures to any hypoglycaemia episode and to episodes of given severity (levels 1, 2 and 3) were examined. Further adjustment was then made for a wider set of potential confounders. The within-person change in continuous outcomes was also summarised (median of 40.4 weeks for type 1 diabetes and 26 weeks for type 2 diabetes). Analyses were conducted separately by type of diabetes.</p><p><strong>Results: </strong>The maximally adjusted association analysis for type 1 diabetes found that cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of neuropathy, kidney disease, retinal disorders and depression, with risk ratios ranging from 1.55 (p=0.002) to 2.81 (p=0.002). Associations of a similar direction were found when level 1 episodes were examined separately but were significant for depression only. For type 2 diabetes cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of death, acute CVD, kidney disease, retinal disorders and depression, with risk ratios ranging from 2.35 (p<0.0001) to 3.00 (p<0.0001). These associations remained significant when level 1 episodes were examined separately. There was evidence of an association between hypoglycaemia episodes of any kind in the previous 10 days and death, acute CVD and retinal disorders in both type 1 and type 2 diabetes, with rate ratios ranging from 1.32 (p=0.017) to 2.68 (p<0.0001). These associations varied in magnitude and significance when examined separately by hypoglycaemia level. Within the range of hypoglycaemia defined by levels 1, 2 and 3, we could not find any evidence of a threshold at which risk of these consequences suddenly became pronounced.</p><p><strong>Conclusions/interpretation: </strong>These data are consistent with hypoglycaemia being associated with an increased risk of adverse events across several body systems in diabetes. These associations are not confined to severe hypoglycaemia requiring assistance.</p>","PeriodicalId":11164,"journal":{"name":"Diabetologia","volume":" ","pages":"2210-2224"},"PeriodicalIF":8.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447089/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00125-024-06225-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims/hypothesis: Whether hypoglycaemia increases the risk of other adverse outcomes in diabetes remains controversial, especially for hypoglycaemia episodes not requiring assistance from another person. An objective of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo-RESOLVE) project was to create and use a dataset of pooled clinical trials in people with type 1 or type 2 diabetes to examine the association of exposure to all hypoglycaemia episodes across the range of severity with incident event outcomes: death, CVD, neuropathy, kidney disease, retinal disorders and depression. We also examined the change in continuous outcomes that occurred following a hypoglycaemia episode: change in eGFR, HbA1c, blood glucose, blood glucose variability and weight.

Methods: Data from 84 trials with 39,373 participants were pooled. For event outcomes, time-updated Cox regression models adjusted for age, sex, diabetes duration and HbA1c were fitted to assess association between: (1) outcome and cumulative exposure to hypoglycaemia episodes; and (2) outcomes where an acute effect might be expected (i.e. death, acute CVD, retinal disorders) and any hypoglycaemia exposure within the last 10 days. Exposures to any hypoglycaemia episode and to episodes of given severity (levels 1, 2 and 3) were examined. Further adjustment was then made for a wider set of potential confounders. The within-person change in continuous outcomes was also summarised (median of 40.4 weeks for type 1 diabetes and 26 weeks for type 2 diabetes). Analyses were conducted separately by type of diabetes.

Results: The maximally adjusted association analysis for type 1 diabetes found that cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of neuropathy, kidney disease, retinal disorders and depression, with risk ratios ranging from 1.55 (p=0.002) to 2.81 (p=0.002). Associations of a similar direction were found when level 1 episodes were examined separately but were significant for depression only. For type 2 diabetes cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of death, acute CVD, kidney disease, retinal disorders and depression, with risk ratios ranging from 2.35 (p<0.0001) to 3.00 (p<0.0001). These associations remained significant when level 1 episodes were examined separately. There was evidence of an association between hypoglycaemia episodes of any kind in the previous 10 days and death, acute CVD and retinal disorders in both type 1 and type 2 diabetes, with rate ratios ranging from 1.32 (p=0.017) to 2.68 (p<0.0001). These associations varied in magnitude and significance when examined separately by hypoglycaemia level. Within the range of hypoglycaemia defined by levels 1, 2 and 3, we could not find any evidence of a threshold at which risk of these consequences suddenly became pronounced.

Conclusions/interpretation: These data are consistent with hypoglycaemia being associated with an increased risk of adverse events across several body systems in diabetes. These associations are not confined to severe hypoglycaemia requiring assistance.

Abstract Image

利用 Hypo-RESOLVE 队列估算低血糖暴露后的后果风险:对胰岛素临床试验汇总数据的二次分析。
目的/假设:低血糖是否会增加糖尿病患者出现其他不良后果的风险仍存在争议,尤其是不需要他人帮助的低血糖发作。低血糖症重新定义低血糖症以获得更好的生活质量(Hypo-RESOLVE)项目的目标之一是创建并使用针对 1 型或 2 型糖尿病患者的临床试验数据集,研究所有低血糖症发作的严重程度与事件结局(死亡、心血管疾病、神经病变、肾脏疾病、视网膜病变和抑郁)之间的关联。我们还研究了低血糖发作后连续性结果的变化:eGFR、HbA1c、血糖、血糖变异性和体重的变化:方法:汇总了来自 84 项试验、39,373 名参与者的数据。对于事件结果,采用经年龄、性别、糖尿病病程和 HbA1c 调整的时间更新 Cox 回归模型来评估:(1) 结果与低血糖事件累积暴露之间的关系;(2) 可能产生急性影响的结果(即死亡、急性心血管疾病、视网膜病变)与过去 10 天内任何低血糖暴露之间的关系。对任何低血糖发作和特定严重程度(1、2 和 3 级)的低血糖发作暴露进行了研究。然后对更广泛的潜在混杂因素进行了进一步调整。此外,还总结了连续性结果的人内变化(1 型糖尿病的中位数为 40.4 周,2 型糖尿病的中位数为 26 周)。分析按糖尿病类型分别进行:对1型糖尿病的最大调整关联分析发现,任何程度的低血糖累积暴露与较高的神经病变、肾脏疾病、视网膜病变和抑郁风险相关,风险比从1.55(p=0.002)到2.81(p=0.002)不等。在单独研究一级发病时,也发现了方向相似的相关性,但只有抑郁症的相关性显著。对于 2 型糖尿病患者来说,任何级别的低血糖累积暴露都与较高的死亡、急性心血管疾病、肾脏疾病、视网膜病变和抑郁风险有关,风险比从 2.35(p=0.002)到 2.81(p=0.002)不等:这些数据表明,低血糖与糖尿病患者多个身体系统发生不良事件的风险增加有关。这些关联并不局限于需要帮助的严重低血糖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetologia
Diabetologia 医学-内分泌学与代谢
CiteScore
18.10
自引率
2.40%
发文量
193
审稿时长
1 months
期刊介绍: Diabetologia, the authoritative journal dedicated to diabetes research, holds high visibility through society membership, libraries, and social media. As the official journal of the European Association for the Study of Diabetes, it is ranked in the top quartile of the 2019 JCR Impact Factors in the Endocrinology & Metabolism category. The journal boasts dedicated and expert editorial teams committed to supporting authors throughout the peer review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信